Abstract:Abstract Introduction: Colorectal Cancer (CRC) is known for its aggressiveness and drug resistance. This has increased the interest in antibody-drug conjugates (ADCs) as a possible therapy. In this study, we aim to investigate the effects of the ADC target TROP2, on the level of epithelial cells and its correlation with survival outcomes in CRC patients. Methods: Single-cell RNA (scRNA) data was downloaded from Gene Expression Omnibus (GEO) for CRC patients and evaluated for TROP2 expression. Patients were grouped into low and high-TROP2 based on median TROP2 expression, and pseudo-bulk analysis was used to find the differentially expressed genes (DEGs). The DEGs were used to find the survival association in the TCGA-CRC cohort. A risk score was built using principal component analysis (PCA) on the TROP2-DEGs and cutoff point was chosen based on survival. Kaplan-Meier curve was used to compare overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS) risk groups. Gene Set Variation Analysis (GSVA) was used to identify the enriched pathways between low- and high-TROP2 in GSE using pseudo-bulk by pooling epithelial cells of individual patients. Results: Of the 10424 cells of 15 different types for 9 CRC patients retrieved from GSE146771, TROP2 was significantly expressed by epithelial cells (n = 766) with mean expression of 1.64 (SD: 1.96, P-value: 0.003) using pseudo-bulk analysis. Three significant DEGs were obtained which are: KIF13B, UCHL3, and PLAC8. These were evaluated for survival association in resectable stages (I-III) CRC patients (n = 419) using PCA to group the patients into low-risk (n = 88) and high-risk (n = 331), using -1.4 as the cutoff point. High risk group showed a better survival with a 1-year survival probability of 94% compared to 90% in the low group and a 5-year survival probability of 74% vs. 46% in the low group. The Kaplan-Meier curve showed that OS, PFS & DFS were significantly better in the low-risk group (p-value = 0.004, 0, 04, and 0.024 respectively). TROP2 and PLAC8 were significantly associated with worse prognosis, whereas UCHL3 was associated with better prognosis (p-value = <0.001), however, KIF3B did not significantly affect the prognosis. APC gene mutation and TP53 were higher in the low-risk group (p-value = 0.004, 0.007 respectively). KRAS-signaling, IL-18-signaling, MET activation of PTK2-signaling were upregulated in high-TROP2 group, while MYC targets, MTORC1 signaling, DNA repair, reactive-oxygen-species signaling, and TCR-signaling were upregulated in low-TROP2. Conclusion: In this study we developed a TROP2-associated risk score that significantly predicted OS, PFS, and DFS in patients with resectable CRC by combining single-cell and bulk-RNA-seq datasets and showing predominant expression of TROP2 in epithelial cells. These findings support the development of TROP2 targeting therapeutics in this space. Citation Format: Noor Nedal Al-Bzour, Ayah Nedal Al-Bzour, Azhar Saeed, Lujia Chen, Anwaar Saeed. Identification of survival-associated epithelial cell markers linked to TROP2 through single-cell and bulk sequencing analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 866.

TROP2 overexpression in colorectal liver oligometastases is associated with poor prognosis after liver resection

Increased expression of Trop2 correlates with poor survival in extranodal NK/T cell lymphoma, nasal type

TROP2 Correlates with Microvessel Density and Poor Prognosis in Hilar Cholangiocarcinoma

Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas.

TROP2 in colorectal carcinoma: associations with histopathology, molecular phenotype, and patient prognosis

TROP 2 is associated with the recurrence of patients with non-muscle invasive bladder cancer

Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway

Programmed Death-Ligand 1 Expression in the Tumour Stroma of Colorectal Liver Oligometastases and Its Association with Prognosis after Liver Resection

Trophoblast Cell-Surface Antigen 2 is a Biomarker and Potential Therapeutic Target in Human Colon Cancer.

Overexpression Of Trophoblast Cell Surface Antigen 2 As An Independent Marker For A Poor Prognosis And As A Potential Therapeutic Target In Epithelial Ovarian Carcinoma

Down-regulation of TROP-2 Predicts Poor Prognosis of Hepatocellular Carcinoma Patients.

The Impact of Trophoblast Cell-Surface Antigen 2 Expression on the Survival of Patients with Gastrointestinal Tumors: A Systematic Review

Abstract 866: Identification of survival-associated epithelial cell markers linked to TROP2 through single-cell and bulk sequencing analysis

Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell carcinoma.

TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non-Small Cell Lung Cancer

High Expression of ROR2 in Cancer Cell Correlates with Unfavorable Prognosis in Colorectal Cancer.

Overexpression of TROP2 Promotes Proliferation and Invasion of Ovarian Cancer Cells

REXO2 up-regulation is positively correlated with poor prognosis and tumor immune infiltration in hepatocellular carcinoma

The clinical research of Trop2 as a potentially therapeutic target in oral tongue squamous cell carcinoma

Clinical impact of TROP2 in non-small lung cancers and its correlation with abnormal p53 nuclear accumulation

Identification of biomarker associated with Trop2 in breast cancer: implication for targeted therapy